Lars Lindegren, Chairman - has held various senior management positions in the pharmaceutical industry including Executive Vice President of Pharmacia AB, Chairman and CEO of Farmitalia Carlo Erba, CEO of Kabi Nutrition and CEO of Astra Pharmaceuticals International.

Jo Klaveness, Professor, M.Sc., M.Sc.Pharm. and Ph.D. in organic chemistry. Jo Klaveness was previously Vice President in Nycomed Imaging AS. Prof. Klaveness is now Professor at School of Pharmacy, University of Oslo, and President and CEO in Drug Discovery Laboratory AS. Prof. Klaveness is the inventor of about 100 patents relating to several new pharmaceutical products on the marked.

Monika Svanberg, BBA is Director of the Oslo Research Park Incubator and affiliated with Springfondet as an Analyst. She has 25 years of experience in business development and marketing from Norway, Denmark and France and has had various positions in nutrition, biotech and information technology companies including CEO and marketing director.

Kjetil Taskén, Professor, M.D., Ph.D. He is together with Professor Hansson the key principal investigator who has formulated and developed the technology now owned by Lauras. He currently has the position as the Centre Director of the Biotechnology Centre, University of Oslo . Taskén has some 150 publications and patents, holds a number of excellence grants and has an outstanding scientific rating. He won the 2002 Anders Jahre’s Medical Award for Younger Scientists (Nordic Price) and has established himself as an international leader in his field. See also http://www.biotek.uio.no

Paul W. Finn, PhD is CEO of InhibOx Ltd, an Oxford-based drug design company. Dr. Finn is a trained medicinal and computational chemist with over 25 years of experience in drug discovery and preclinical drug development. Formerly, Dr. Finn held drug design and computational chemistry positions at Smith Kline Beechham and Pfizer, and as Director for Chemistry and subsequently Director of R&D in Prolifix and Topo Target.